Markets Roth starts Cellectar Biosciences at buy; PT $11 Roth Capital Partners launched coverage of Cellectar Biosciences (NASDAQ:CLRB) with a “buy” rating and $11 price target. The stock closed at $2.29 on Sept. 12. Cellectar is developing CLR 131, a targeted... September 13, 2019